Evaluation of Annexin A2 as a Novel Diagnostic Marker for Hepatocellular Carcinoma in Egyptian Patients
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 90
- 主要终点
- serum Annexin A2 in patients with hepatocellular carcinoma, chronic liver disease and healthy subjects
研究概览
简要总结
This study aimed to investigate the clinical utility of Annexin A2 serum level as a novel diagnostic marker of hepatocellular carcinoma (HCC) and to correlate its level with alpha fetoprotein the current marker ofhepatocellular carcinoma (HCC).
详细描述
This study was carried out in HCC clinic , Ain Shams University Hospitals, Cairo; Egypt and included :Group 1: Fifty patients with early stage hepatocellular carcinoma(BCLC stage A); Group 2:Twenty five patients with chronic liver disease diagnosed based on clinical, laboratory, and ultrasonographic investigations; Control Group: Fifteen healthy, age and sex-matched subjects with seronegative hepatitis viral markers .All groups were subjected to thorough history taking, full clinical examination, and laboratory investigations including viral hepatitis markers: HBsAg and HCV antibodies using ELISA technique and HCV RNA using real time PCR for HCV antibody positive patients, AFP by electrochemiluminescence and Annexin A2 estimation using ELISA technique.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Inclusion criteria for HCC cases:
- •Confirmed diagnosis of HCC according to the European association of study of liver diseases [13].
- •Early stage HCC (Stage A), using the Barcelona Clinic Liver Cancer (BCLC) staging system, (single or 3 nodules < 3cm PS 0) For all participants:.
- •Informed consent from all participants before enrollment in the study.
排除标准
- •For HCC patients:
- •1-Imtermediate or advanced stage HCC as defined by BCLC
- •Major vascular tumor invasion or metastasis confirmed by radiological imaging studies.
- •Patients with other suspected solid malignancies or metastatic liver tumors,
- •Other types of chronic liver diseases (CLD) such as autoimmune hepatitis and primary biliary cirrhosis.
- •For all participants:
- •Refusal to participate in the study
结局指标
主要结局
serum Annexin A2 in patients with hepatocellular carcinoma, chronic liver disease and healthy subjects
时间窗: 1 month
to determine the clinical utility of Annexin A2 serum level as a novel diagnostic marker of hepatocellular carcinoma (HCC) and to correlate its level with alpha fetoprotein the current marker of (HCC).
次要结局
未报告次要终点
研究者
Iman Fawzy Montasser
Lecturer of tropical medicine , Ain Shams university
Ain Shams University